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Reprogramming of cellular metabolism by oncogenic mutations probably creates specific vulnerabilities that
could be exploited therapeutically. In this issue of Cancer Cell, Sourbier and colleagues show that kidney
cancers lacking fumarate hydratase display increased sensitivity to agents that interfere with their ability
to cope with reactive oxygen species.Kidney cancer, which is believed to arise
from renal tubular epithelial cells, is one
of the ten leading causes of cancer death
in the United States. There are several
histological subtypes of kidney cancer.
The most common kidney cancer is
clear cell renal carcinoma. Other variants
include papillary renal cancer, chromo-
phobe renal cancer, and oncocytoma.
The elucidation of molecular pathways
that play critical roles in the various forms
of kidney cancer has been aided by
the discovery of the genes responsible
for hereditary kidney cancer syndromes.
For example, germline loss-of-function
VHL mutations cause von Hippel-Lindau
disease, which is characterized by an
increased risk of clear cell renal carci-
noma. As predicted by this knowledge,
somatic VHLmutations are common initi-
ating events in most sporadic clear cell
renal carcinomas.
Two forms of hereditary papillary renal
cancer have been described based on
histological and clinical features. Type 1
papillary renal cancer is caused by acti-
vating germline mutations in MET. Type
2 papillary renal cancer is caused by inac-
tivating germline mutations of the fuma-
rate hydratase (FH) gene. Interestingly,
inactivation of succinate dehydrogenase
(SDH), the enzyme that acts immediately
upstreamof FH, has been linked to a small
subset of clear cell renal cancers.
Activating mutations such as those
involvingMET present less of a therapeu-
tic challenge than loss-of-function muta-
tions. In theory, however, there are at
least two ways to target a cancer that
was instigated by a loss-of-function mu-
tation. The first is to exploit epistatic rela-tionships, targeting proteins that are acti-
vated by virtue of the loss-of-function
mutation and play causal roles down-
tream in transformation. For example,
the VHL gene product, pVHL, normally in-
hibits the hypoxia-inducible factor (HIF).
Deregulation of HIF, in particular HIF2,
drives the formation of pVHL-defective
tumors. Drugs that inhibit the HIF-res-
ponsive growth factor VEGF are already
approved for clear cell renal cancer, and
a drug that specifically inhibits HIF2 is
about to be tested for this indication.
Deregulation of HIF is also a feature
of SDH and FH mutant tumors because
the pathological accumulation of succi-
nate and fumarate, respectively, inhibits
various 2-oxoglutarate-dependent en-
zymes, including the prolyl hydroxylases
that mark HIF for recognition by pVHL.
According to the law of parsimony, or
‘‘Occams Razor,’’ HIF should also be the
driving force in kidney cancers caused
by SDH or FH mutations. Moreover, HIF
is usually associated with a poor prog-
nosis in cancer, and it is plausible that
HIF could generally promote kidney tumor
growth based on its known functions.
However, in some settings, HIF stabiliza-
tion could merely be the consequence of
aggressive tumor growth, and resulting
hypoxia, rather than its cause. It is also
becoming clear that the biological effects
of HIF are highly contextual and might
even differ among HIF paralogs. For
example, HIF2 is a clear cell renal carci-
noma oncogene, whereas HIF1 appears
to act as a clear cell renal carcinoma sup-
pressor (Shen et al., 2011). Notably, dele-
tion of HIF1 in genetically engineered
mice lacking FH actually worsened theCancer Cell 26,renal cyst formation and cellular atypia
caused by the latter (Adam et al., 2011).
It is therefore still unclear what role HIF
plays in papillary renal cancers.
The second approach is to exploit syn-
thetic lethality, looking for proteins that
are essential in cells carrying the loss-of-
function mutation but dispensable in
wild-type cells. Synthetic lethality can
form the basis for dramatic clinical re-
sponses. For example, a complete remis-
sion induced by a CHK1 kinase inhibitor
in an otherwise failed clinical trial was
recently linked to the presence of a muta-
tion affecting the MRE11 complex in the
responding patient’s tumor (Al-Ahmadie
et al., 2014). CHK1 and MRE11 play
complementary roles in DNA repair and
display synthetic lethality in model organ-
isms. In two recent preclinical studies,
FH/ cells were found to be hyper-
dependent on heme oxygenase activity
and exogenous arginine (Frezza et al.,
2011; Zheng et al., 2013). Whether these
insights can be translated into the clinic
remains to be determined.
In this issue of Cancer Cell, Sourbier
et al. (2014) screened a small compound
library in search of drugs capable of
selectively killing FH-defective papillary
renal cancer cells compared to isogenic
cells in which wild-type FH activity was
restored. They discovered that van-
detanib, which inhibits multiple kinases
including ABL, displays such a profile.
In cell culture studies, the authors
demonstrated that inhibition of ABL was
both sufficient and necessary for the anti-
proliferative effects of vandetanib on FH-
defective renal cancer cells. In particular,
they showed that eliminating ABL1 withDecember 8, 2014 ª2014 Elsevier Inc. 779
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Previewsmultiple small interfering (si)/micro(mi)
RNAs phenocopied the effects of van-
detanib and that this effect could be
reversed with wild-type, but not cata-
lytically-dead, versions of ABL1 encoded
by si/miRNA-resistant cDNAs. In addition,
they showed that ABL inhibitors structur-
ally unrelated to vandetanib also preferen-
tially killed FH-defective cells compared
to FH-proficient cells. Conversely, over-
expression of a vandetanib-resistant
ABL1 variant rescued cells from vandeta-
nib-induced killing.
Loss of FH affects mitochondrial func-
tion directly and also has indirect effects
on both glucose metabolism and oxida-
tive phosphorylation because of the inap-
propriate activation of HIF (vide supra).
The authors provide compelling evidence
that increasedROS sensitizes cells to loss
of ABL1 activity.
Why does fumarate and the resulting
increase in ROS increase dependence
on ABL1? ROS induces ABL1 kinase ac-
tivity, which the authors show promotes
the nuclear translocation of NRF2. Earlier
studies showed that fumarate also in-
creases NRF2 stability by causing the
succinylation, and hence inactivation,
of the NRF2 ubiquitin ligase KEAP1
(Adam et al., 2011; Ooi et al., 2011).
NRF2 transcriptionally activates genes
that decrease ROS levels or mitigate their
effects. NRF2 promotes tumor growth in a
variety of epithelial cancers, including
both clear cell and papillary renal cancers
(Li et al., 2013; Ooi et al., 2013; Sourbier
et al., 2014).
A caveat here, however, is that the
authors’ cell culture studies were largely
done in media lacking pyruvate, which
can act as an ROS scavenger, and in the
presence of 21% oxygen, which itself
can cause redox stress (Parrinello et al.,780 Cancer Cell 26, December 8, 2014 ª2012003). Notably, the effects of ABL1 loss
on cell viability were attenuated in stan-
dard, pyruvate-containing, media.
Importantly, however, Sourbier et al.
(2014) showed that vandetanib does
have antitumor activity against FH-
defective tumors in nude mice assays,
especially when combined with AMPK
agonists, which activate the SIRT1 de-
acetylase and thereby decrease NRF2
activity further. In fact, the combination
appeared capable of curing mice bearing
such tumors. A caveat is that vandetanib
inhibits several kinases (in addition to
ABL1) implicated in renal tumorigenesis,
including EGFR and VEGFR. Although
the authors clearly demonstrated the
importance of ABL1 with respect to the
effects of vandetanib in cell culture exper-
iments, it remains to be determined which
vandetanib target, or targets, are res-
ponsible for the antitumor effects they
observed in mice. In this regard, it is so-
bering that ABL1 inhibitors such as imati-
nib and dasatanib have demonstrated
very little activity, at least as single agents,
in epithelial cancers including kidney can-
cers. It will be important to ask if the pre-
clinical antitumor effects observed with
vandetanib can be replicated with other
ABL1 inhibitors and whether the clinical
activity of ABL1 inhibitors can indeed be
enhanced by concurrent administration
with an AMPK agonist, focusing initial
proof-of-concept studies on FH defective
kidney cancers.
Surprisingly, FHmutations are relatively
rare in sporadic papillary renal cancers
(Ooi et al., 2013). This might, among
several possibilities, reflect the existence
of a particular window during develop-
ment when renal cells are permissive for
transformation by fumarate. Regardless,
very few epithelial cancers carry FHmuta-4 Elsevier Inc.tions. It will therefore be important to
explore whether other tumors character-
ized by redox stress, especially when
associated with normoxic HIF activation,
are likewise sensitive to combined ABL1
inhibition and AMPK activation.REFERENCES
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